Get the Stockscreener App
10.11
0.10%
0.010
Drugs Made In America Acquisition Corp stock is traded at $10.11, with a volume of 1,294.
It is up +0.10% in the last 24 hours and up +0.80% over the past month.
Drugs Made In America Acquisition Corp is a blank check company.
See More
Previous Close:
$10.10
Open:
$10.11
24h Volume:
1,294
Relative Volume:
0.01
Market Cap:
$338.86M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+0.30%
1M Performance:
+0.80%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$10.10
$10.11
1-Week Range:
$10.07
$10.12
52-Week Range:
$9.96
$10.27
Drugs Made In America Acquisition Corp Stock (DMAA) Company Profile
Name
Drugs Made In America Acquisition Corp
Sector
Industry
Phone
954-870-3104
Address
2 PELICAN DR., FORT LAUDERDALE
Compare DMAA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DMAA
Drugs Made In America Acquisition Corp
|
10.11 | 338.86M | 0 | 0 | 0 | 0.00 |
|
LION
Lionsgate Studios Corp
|
7.22 | 2.06B | 0 | 0 | 0 | 0.00 |
|
AACT
Ares Acquisition Corporation Ii
|
11.27 | 697.16M | 0 | 16.92M | -1.35M | 0.29 |
|
ANSC
Agriculture Natural Solutions Acquisition Corp
|
10.75 | 461.44M | 0 | 1.30M | 0 | 0.0301 |
|
EQV
Eqv Ventures Acquisition Corp
|
10.23 | 455.09M | 0 | 0 | 0 | 0.00 |
Drugs Made In America Acquisition Corp Stock (DMAA) Latest News
Layoff Tracker: Ono Cuts 83 Employees in Massachusetts - BioSpace
Financial Snapshot: Analyzing East West Bancorp, Inc (EWBC)’s Key Ratio Metrics - DWinneX
Metric Deep Dive: Understanding Drugs Made In America Acquisition Corp (DMAA) Through its Ratios - DWinneX
Market Resilience: Four Corners Property Trust Inc (FCPT) Finishes Weak at 27.86, Down -1.90 - DWinneX
Daily Progress: Coca-Cola Europacific Partners Plc (CCEP) Drop -0.78, Closing at 88.15 - DWinneX
Financial Analysis: Bio-Key International Inc (BKYI)’s Ratios Unveil Key Insights - DWinneX
Ratio Revelations: Amerant Bancorp Inc (AMTB)’s Financial Metrics in the Spotlight - DWinneX
Closing Strong: Lulus Fashion Lounge Holdings Inc (LVLU) Ends at 0.41, Down -7.73 from Last Close - DWinneX
AstraZeneca | Pharmaceuticals, Vaccines, & Facts - Britannica
Pfizer Inc. - Britannica
WEBTOON Entertainment Inc. (NASDAQ:WBTN) Receives Consensus Recommendation of “Moderate Buy” from Brokerages - Defense World
ICR, the Leading SPAC Communications and Advisory Firm, Publishes its Q1 2025 SPAC Market Update & Outlook - Business Wire
Theratechnologies’ stock soars on disclosure of acquisition offer by U.S. company - Montreal Gazette
'I bought their dream': How a US company's huge land deal in Senegal went bust - Yahoo
Drugs Made In America Acquisition Corp. (DMAA) reports earnings - qz.com
Bright Green Unveils Massive $2B Cannabis Strategy with Zero Shareholder Dilution - StockTitan
Bright Green Corporation Announces the next steps for the completion of its restructuring plan - The Manila Times
DRUGS MADE IN AMERICA ACQUISITION CORP- The GF Score's 5 Key Aspects of Analysis - GuruFocus.com
India-based Syngene acquires its first US biologics site - Manufacturing Dive
Drugmakers Mallinckrodt and Endo get a bump from tariffs in $6.7 billion merger - Reuters
7 Best Weight Loss Drug Stocks to Buy in 2025 | Investing | U.S. News - U.S News & World Report Money
Brokerages Set TWFG, Inc. (NASDAQ:TWFG) Target Price at $31.86 - Defense World
BridgeBio Oncology Therapeutics (BBOT) and Helix Acquisition Corp. II Announce Business Combination Agreement to Create Publicly Listed Biotechnology Company Advancing a Pipeline of RAS and PI3Kα-Targeting Medicines - Business Wire
Lilly plans to more than double U.S. manufacturing investment since 2020 exceeding $50 billion | Eli Lilly and Company - Eli Lilly and Company
A little-known Chinese company made a drug that beat the world’s biggest-selling medicine - CNN
Drugs Made in America Acquisition Corp. Forms Advisory Team to Pursue Pharmaceutical Business Acquisitions - Nasdaq
Popular cannabis brand declares Chapter 11 bankruptcy - TheStreet
Fierce Pharma Asia—Novo Nordisk's fraud accusation; AstraZeneca's China deal; Ono's FDA nod - Fierce Pharma
Drugs Made In America Acquisition Corp. Announces Trading Options for Public Offering Units Starting February 25, 2025 - Nasdaq
Mink Ventures Completes Acquisition of Warren Ni, Cu, Co Patents - The Manila Times
Drugs Made In America Acquisition Corp. Announces Closing of Full Exercise of IPO Over-Allotment Option - TradingView
Drugs Made In America Acquisition Corp. Secures Additional $30 Million in IPO as Underwriter Fully Exercises Overallotment Option - Nasdaq
U.S. investors, Big Pharma race to find new medicines in China - CNBC
Drugs Made In America Acquisition Corp.’s $200 Million Initial Public Offering - Global Legal Chronicle
Trump wants to put tariffs on prescription drugs. Experts warn it could backfire. - Yahoo Finance
Bain throws down $3.3B to acquire Japan's Mitsubishi Tanabe Pharma - Fierce Pharma
United Parcel Service (UPS) | History, Services, & Facts - Britannica
Merck touts 20 new ‘blockbuster’ drugs in development with $50 billion potential - Fortune
Our History - Baxter
U.S. IPO Weekly Recap: Active January Closes Out With Several Sizable IPOs - Seeking Alpha
IPO NewsUS IPO Weekly Recap: Active January closes out with several sizable IPOs - renaissancecapital.com
Drugs Made In America Acquisition Corp. Announces Closing of $200,000,000 Initial Public Offering - The Manila Times
Drugs Made In America Acquisition Corp. Completes $200 Million IPO on Nasdaq - Nasdaq
Drugs Made In America Acquisition Prices $200 Million IPO - MarketScreener
Drugs Made in America Acquisition Corp. (DMAAU) Prices $200M IPO - SPAC Insider
Bright Green Corporation Has Signed Agreement with Majority - GlobeNewswire
How UnitedHealth and Rivals Made $7.3 Billion Marking Up Drugs: FTC - Newsweek
How a Company Makes Millions Off a Hospital Program Meant to Help the Poor - The New York Times
How Trump’s Greenland demands could impact Ozempic costs - The Hill
Johnson & Johnson Strengthens Neuroscience Leadership with Acquisition of Intra-Cellular Therapies, Inc. - Johnson & Johnson
The top 10 biopharma M&A deals of 2024 - Fierce Pharma
Drugs Made In America Acquisition Corp Stock (DMAA) Financials Data
There is no financial data for Drugs Made In America Acquisition Corp (DMAA). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.53%
0.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):